Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

11,410 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
TP53 signature predicts pathological complete response after neoadjuvant chemotherapy for breast cancer: Observational and confirmational study using prospective study cohorts.
Takahashi S, Sato N, Kaneko K, Masuda N, Kawai M, Hirakawa H, Nomizu T, Iwata H, Ueda A, Ishikawa T, Bando H, Inoue Y, Ueno T, Ohno S, Kubo M, Yamauchi H, Okamoto M, Tokunaga E, Kamigaki S, Aogi K, Komatsu H, Kitada M, Uemoto Y, Toyama T, Yamamoto Y, Yamashita T, Yanagawa T, Yamashita H, Matsumoto Y, Toi M, Miyashita M, Ishida T, Fujishima F, Sato S, Yamaguchi T, Takahashi F, Ishioka C. Takahashi S, et al. Among authors: takahashi f. Transl Oncol. 2024 Oct;48:102060. doi: 10.1016/j.tranon.2024.102060. Epub 2024 Jul 24. Transl Oncol. 2024. PMID: 39047382 Free PMC article.
Phase II trial of cetuximab plus irinotecan for oxaliplatin- and irinotecan-based chemotherapy-refractory patients with advanced and/or metastatic colorectal cancer: evaluation of efficacy and safety based on KRAS mutation status (T-CORE0801).
Soeda H, Shimodaira H, Gamoh M, Ando H, Isobe H, Suto T, Takahashi S, Kakudo Y, Amagai K, Mori T, Watanabe M, Yamaguchi T, Kato S, Ishioka C. Soeda H, et al. Among authors: takahashi s. Oncology. 2014;87(1):7-20. doi: 10.1159/000360989. Epub 2014 Jun 24. Oncology. 2014. PMID: 24968756 Clinical Trial.
Safety verification trials of mFOLFIRI and sequential IRIS + bevacizumab as first- or second-line therapies for metastatic colorectal cancer in Japanese patients.
Kato S, Andoh H, Gamoh M, Yamaguchi T, Murakawa Y, Shimodaira H, Takahashi S, Mori T, Ohori H, Maeda S, Suzuki T, Kato S, Akiyama S, Sasaki Y, Yoshioka T, Ishioka C; Tohoku Clinical Oncology Research and Education. Kato S, et al. Among authors: takahashi s. Oncology. 2012;83(2):101-7. doi: 10.1159/000339541. Epub 2012 Jul 9. Oncology. 2012. PMID: 22777333 Clinical Trial.
11,410 results
You have reached the last available page of results. Please see the User Guide for more information.